MedTrace Logo

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

NCT04133922 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2022-03-22

No results posted yet for this study

Summary

GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle oxygenation

Conditions

Interventions

DRUG

GLP-1

glucagon-like peptide 1

DRUG

Insulin

we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp

DRUG

Dextrose 20 % in Water

We are using Dextrose to maintain Euglycemia during the insulin clamp

Sponsors & Collaborators

  • American Diabetes Association

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Virginia

    lead OTHER

Principal Investigators

  • Zhenqi Liu, MD · Department of Endocrinology, University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2023-10-31
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133922 on ClinicalTrials.gov